This invention protects the use of nicotine, analogues thereof precursors thereof or its derivates for treatment of inflammatory, infectious, candidal or degenerative (f the joints and/or of the central nNervous system, of kidneys, the lungs, liver), depression, obesity, bone disease and the like, which can be improved by means of intensification of the actions of ±-MSH, given the fact that this hormone are extraordinary properties: e.g. , it has an antipyretic potency 20,000 times as great as acetaminophen, its antimicrobian potency, is comparable to gentamycine, it is the best anticandidiasic known； it inhibits apoptosis of various stem cells, and significantly modulates the inmmune reactions, and therefore the use of agents that affect its release may have significant therapeutic potential. This patent protects the use of nicotine, analogues thereof, precursors thereof or its derivates for the purpose of increasing and/or reducing the bioavailability of ±-MSH in blood and/or central or peripheral tissues to accentuate or diminish the effect of the ±-MSH by means of changes in its concentration or its effect on the corresponding receptors of any cell, tissue or organ in the body, administrated for therapeutic and/or prophylactic purposes in the short medium and/or long term.
